Skip to main content
BMC Medical Co., Ltd. logo

BMC Medical Co., Ltd. — Investor Relations & Filings

Ticker · 301367 ISIN · CNE100005WQ4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 528 across all filing types
Latest filing 2026-05-11 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 301367

About BMC Medical Co., Ltd.

https://www.bmc-medical.com

BMC Medical Co., Ltd. specializes in the development and distribution of diagnostic and therapeutic solutions for sleep-disordered breathing and chronic respiratory conditions. The company’s core product portfolio includes continuous positive airway pressure (CPAP) devices, bilevel positive airway pressure (BPAP) systems, and high-flow oxygen therapy equipment. These are complemented by a range of patient interfaces, including nasal, pillow, and full-face masks. BMC integrates digital health capabilities through cloud-based management platforms, enabling remote data analysis and patient monitoring. By focusing on technical innovation and clinical efficacy, the company provides integrated respiratory care systems designed to improve patient compliance and therapeutic outcomes for conditions such as obstructive sleep apnea and chronic obstructive pulmonary disease.

Recent filings

Filing Released Lang Actions
中国国际金融股份有限公司关于北京瑞迈特医疗科技股份有限公司持续督导保荐总结报告书
Regulatory Filings Classification · 85% confidence The document is a continuous sponsor supervision summary report (“持续督导保荐总结报告书”) issued by the sponsor (China International Capital Corp) upon the completion of its ongoing supervision period for an IPO on the Shenzhen GEM. It is neither an annual or interim financial report, nor an earnings release, proxy statement, or management presentation. It is a compliance‐oriented report under Chinese securities regulations, summarizing due diligence and supervisory activities. This type of regulatory compliance filing that does not fit other specific categories falls under the fallback category “Regulatory Filings” (RNS).
2026-05-11 Chinese
中国国际金融股份有限公司关于北京瑞迈特医疗科技股份有限公司2025年度持续督导跟踪报告
Regulatory Filings Classification · 90% confidence The document is a continuous supervision tracking report prepared by the sponsor (保荐人) for the listed company, detailing regulatory compliance activities, site inspections, internal control reviews, sponsor findings, and corrective measures. It is not a financial report like an annual or interim report, nor an earnings release, proxy statement, or any other specific category. It is a compliance filing required by the exchange, fitting the fallback “Regulatory Filings” category.
2026-05-11 Chinese
关于公司2025年限制性股票激励计划第一个归属期归属结果暨股份上市的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Beijing Ruimait Medical Technology Co., Ltd. regarding the results of the first vesting period of the company's 2025 restricted stock incentive plan and the listing of the vested shares. It details the number of shares vested, the number of participants, the source of shares, the adjusted grant price, and the listing date of the shares. It also includes information about the approval process, performance conditions, and legal opinions related to the stock incentive plan. The document is a formal announcement about the vesting and listing of restricted stock under a stock incentive plan, which is a capital/financing update related to equity incentives and share issuance. It is not a full financial report, audit report, or management report, nor is it a regulatory filing or a proxy statement. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (8616 characters) and detailed content support this classification with high confidence.
2026-05-07 Chinese
中国国际金融股份有限公司关于北京瑞迈特医疗科技股份有限公司使用闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (China International Capital Corporation) regarding the use of idle raised funds by Beijing Ruimaite Medical Technology Co., Ltd. for cash management. It references regulatory rules about the management and use of raised funds, details the amount raised, the intended projects, the cash management plan, risk controls, and the board's approval. The document is not a financial report like an Annual Report or Interim Report, nor is it a simple announcement. It is a formal verification or audit opinion related to the use of raised funds, which fits the category of an Audit Report / Information (AR). The document length is 4307 characters, which is substantial and contains detailed content, not just an announcement or certification. Therefore, the best classification is AR (Audit Report / Information). FY 2026
2026-04-22 Chinese
2025年度总经理工作报告
Management Reports Classification · 95% confidence The document is titled as the "2025年度总经理工作报告" which translates to "2025 Annual General Manager Work Report." It contains a detailed summary of the company's management activities, governance, operational performance, R&D, talent management, and outlook for the next year. It includes financial figures such as revenue and net profit, and discusses strategic plans and business outlook. The document is about management's detailed explanation of the company's results and future plans, which aligns with the definition of a Management Report (MDA). The document length is 3189 characters, which is relatively short but contains substantive content rather than just an announcement or certification. It is not an Annual Report (10-K) or Interim Report (IR) because it lacks full financial statements and comprehensive financial disclosures. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it is the report itself, not just an announcement. Therefore, the best classification is Management Reports (MDA).
2026-04-22 Chinese
关于变更注册资本及修订《公司章程》的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Beijing Ruimait Medical Technology Co., Ltd. regarding changes in registered capital and amendments to the company's articles of association. It details board resolutions about capital increase via capital reserve conversion to shares and corresponding amendments to the company charter. It also mentions that these proposals will be submitted to the 2025 annual shareholders meeting for approval. The document is a formal public announcement of corporate governance and capital structure changes, not a full report or financial statement. It fits the category of Share Issue/Capital Change announcements, as it concerns changes in registered capital and share capital structure.
2026-04-22 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.